Paroxetine Mesylate Suppresses Colorectal Cancer via MET/ERBB3 Inhibition

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, with a significant proportion of patients presenting metastatic disease at diagnosis. Standard chemotherapy regimens, including 5-fluorouracil, are often limited by modest efficacy and the emergence of drug resistance. The cost and timeline of developing new oncology agents have led to increased interest in drug repositioning—identifying new therapeutic uses for established compounds. In this context, Won-Jun Jang and colleagues (reference study) investigated whether Paroxetine Mesylate, widely prescribed as a selective serotonin reuptake inhibitor (SSRI), could exert direct anticancer effects in CRC models and elucidated the mechanisms underlying its action.

Key Innovation from the Reference Study

The key innovation of this study lies in its demonstration that Paroxetine Mesylate, beyond its primary neuropsychiatric indications, displays significant anticancer activity against human colorectal cancer cells. Specifically, the study identifies Paroxetine Mesylate as a dual inhibitor of the receptor tyrosine kinases MET and ERBB3, which are implicated in CRC progression, survival, and metastasis. This positions Paroxetine Mesylate not only as a selective serotonin reuptake inhibitor but also as a molecule with multi-kinase inhibitory properties relevant to oncology. This mechanistic insight extends the therapeutic potential of Paroxetine Mesylate into the realm of translational cancer research.

Methods and Experimental Design Insights

The researchers employed both in vitro and in vivo experimental models to assess the anticancer properties of Paroxetine Mesylate. Two human colorectal cancer cell lines (HCT116 and HT-29) were selected for cell viability, apoptosis, colony formation, and 3D spheroid assays. The compound was administered at varying concentrations to determine dose-dependent effects. In addition, the study utilized athymic nude mice bearing HT-29 xenografts to evaluate the impact of Paroxetine Mesylate on tumor growth in vivo. Western blotting and pathway analysis were performed to dissect the molecular mechanisms, focusing on the activity of MET and ERBB3 kinases and downstream signaling cascades such as AKT, ERK, p38, JNK, and caspase-3.

Core Findings and Why They Matter

In vitro: Treatment with Paroxetine Mesylate led to a marked reduction in cell viability in both HCT116 and HT-29 cell lines. The reduction in proliferation was associated with increased apoptotic cell death, as evidenced by activation of caspase-3 and induction of JNK signaling. Notably, the compound also suppressed colony formation and the growth of 3D spheroids, which are considered robust models for evaluating tumorigenic potential.

Mechanistic Insights: The study provided compelling evidence that Paroxetine Mesylate acts as a receptor tyrosine kinase MET inhibitor and an ERBB3 kinase inhibitor. Inhibition of these kinases resulted in downstream suppression of AKT, ERK, and p38 phosphorylation, pathways that are critical for tumor cell survival and proliferation. The dual inhibition of MET and ERBB3 distinguishes Paroxetine Mesylate from conventional SSRIs and underscores its value in multi-kinase targeting strategies.

In vivo: In the mouse xenograft model, systemic administration of Paroxetine Mesylate significantly suppressed the growth of HT-29 tumors, corroborating the in vitro findings and supporting the translational relevance of these observations (reference study).

These findings are significant because they suggest that Paroxetine Mesylate could be repurposed as an anticancer agent, particularly in CRC subtypes where MET and ERBB3 pathways are active. The established safety profile and pharmacokinetics of Paroxetine Mesylate as a psychiatric medication facilitate its consideration for oncology applications and accelerate the potential path to clinical translation.

Comparison with Existing Internal Articles

The anticancer potential of Paroxetine Mesylate has been highlighted in several recent reviews and research summaries. For example, "Paroxetine Mesylate Inhibits Colorectal Cancer via MET/ERBB3 Suppression" synthesizes evidence that aligns with the reference study, confirming the compound's inhibitory effects on proliferation and survival of CRC cells through MET and ERBB3 targeting. Similarly, "Paroxetine Mesylate: SSRI and Multi-Kinase Inhibitor Insights" provides an integrated perspective on this molecule as both a psychiatric and oncology tool, referencing its high affinity for the serotonin transporter and its capacity to inhibit kinases relevant to cancer and neurology. These internal resources reinforce the mechanistic and translational context established by Jang et al., and collectively support the notion that Paroxetine Mesylate's multi-target profile—including its activity as a cytochrome P450 inhibitor (notably CYP2D6), G protein-coupled receptor kinase 2 inhibitor, and KIT kinase inhibitor—broadens its research utility beyond psychiatric disorders.

Limitations and Transferability

While the reference study provides robust preclinical evidence, several limitations must be considered. First, the experiments were conducted in selected CRC cell lines and immunodeficient mouse models, which may not fully recapitulate the heterogeneity and immune landscape of human tumors. Second, the observed anticancer effects are dose-dependent and may require concentrations that differ from those used therapeutically for psychiatric indications. Third, the impact of Paroxetine Mesylate's inhibitory activity on other kinases (e.g., KIT, JAK) and its modulation of cytochrome P450 enzymes (notably CYP2D6) raises questions about off-target effects, drug-drug interactions, and metabolic liabilities in oncology settings. Therefore, while transferability to human clinical scenarios is promising due to prior safety data, further validation in diverse CRC models, pharmacokinetic studies, and ultimately clinical trials will be necessary.

Protocol Parameters

• Cell viability assays: Paroxetine Mesylate was applied at concentrations ranging from 7 to 26 μM to HCT116 and HT-29 cells for 24–72 hours, resulting in significant inhibition of proliferation and induction of apoptosis (reference study).
• Colony and 3D spheroid formation: Treatment protocols involved continuous exposure to Paroxetine Mesylate at similar concentrations, monitoring reduction in colony number and spheroid size as endpoints.
• In vivo dosing (mouse xenograft): Athymic nude mice bearing HT-29 tumors received regular systemic administration of Paroxetine Mesylate. Tumor volume was monitored over time; refer to the original publication for precise dosing schedules and controls.
• Mechanistic pathway analysis: Western blotting for MET, ERBB3, AKT, ERK, p38, JNK, and caspase-3 phosphorylation/cleavage was used to confirm pathway inhibition and apoptosis induction.
• Practical workflow recommendation: For researchers establishing similar CRC models or kinase inhibition workflows, start with in vitro concentration ranges of 7–26 μM and in vivo dosing guided by the referenced xenograft protocols, adjusting for local ethical and pharmacokinetic considerations.

Why this cross-domain matters, maturity, and limitations

Paroxetine Mesylate is classically known for its role as a selective serotonin reuptake inhibitor in psychiatric disorders. The discovery of its multi-kinase inhibitory activity—specifically as a MET and ERBB3 kinase inhibitor—demonstrates a successful instance of drug repositioning. This cross-domain application is significant because it leverages existing pharmacological and safety data, potentially expediting the development of new cancer therapies. However, the maturity of this approach is currently preclinical, with limitations stemming from the need for further validation in human studies, assessment of off-target effects, and optimization of dosing regimens distinct from psychiatric practice.

Research Support Resources

Researchers seeking to replicate or extend these findings may utilize Paroxetine Mesylate (SKU C8698) for in vitro and in vivo studies targeting receptor tyrosine kinases and exploring multi-pathway inhibition in colorectal cancer models. APExBIO offers detailed specifications, including storage and handling recommendations, to facilitate robust experimental design. For further methodological context and protocol optimization, internal articles such as "Multi-Target Strategies for Translational Research" provide additional workflow insights relevant to oncology and pharmacology research.